Perimeter Medical Imaging AI Announces Acceleration of Expiry Date of Warrants

Rhea-AI Summary

Perimeter Medical Imaging AI has announced an acceleration of the expiry date for its warrants, originally issued on June 29, 2020. These warrants, which allow purchase of common shares at $2.00, will now expire on March 8, 2021. This decision was made as the company's common shares had a 15-day volume-weighted average trading price of $3.0860, exceeding the $3.00 threshold set in the Warrant Indenture. If all 2,694,575 outstanding warrants are exercised, the company could raise approximately $5.39 million.

Positive

• Company could raise approximately $5.39 million if all warrants are exercised.
• Warrant expiration acceleration indicates strong market performance with shares trading above $3.00.

Negative

• No assurance that any warrants will be exercised before the expiration date.

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need, announced today it has elected to exercise its right under the terms of a warrant indenture dated June 29, 2020 (the “Warrant Indenture”) between the Company and Computershare Trust Company of Canada (the “Warrant Agent”) to accelerate the expiry date of the warrants to purchase common shares of the Company (“Common Shares”) issued on June 29, 2020 to investors in Perimeter’s private placement financing of units completed on that day (the “Warrants”). Each Warrant is exercisable to acquire one Common Share at an exercise price of $2.00.

The expiry date of the Warrants has been accelerated to 4:00 p.m. (Toronto Time) on March 8, 2021. Any Warrants remaining unexercised after 4:00 p.m. (Toronto Time) on March 8, 2021 will be cancelled and will thereafter be of no force or effect.

Pursuant to the Warrant Indenture, the Company has the right to accelerate the expiry date of the Warrants to a date that is 30 days following delivery of an Acceleration Notice (as described in the Warrant Indenture) if, the 15-day volume-weighted average trading price of the Common Shares on the TSX Venture Exchange (the “TSXV”) equals or exceeds $3.00. The Company calculates that, between January 11, 2021 and January 29, 2021, the 15-day volume-weighted average trading price of the Common Shares on the TSXV was $3.0860.

The Company calculated the 15-day volume-weighted average trading price for the period using the daily volume and VWAP of the Common Shares calculated by the Exchange to determine that the Acceleration Event had occurred. More information on the trading and price history of the Common Shares can be found at the following web link: https://money.tmx.com/en/quote/PINK.

If you hold Warrants, in order to exercise your Warrants prior to 4:00 p.m. (Toronto Time) on March 8, 2021 you must complete and deliver to the Warrant Agent the Exercise Form attached to the Warrant Certificate along with a certified cheque, bank draft or money order payable to or to the order of the Company for the aggregate exercise price of the Warrants. The address of the Warrant Agent for the exercise of your Warrants is:

Computershare Trust Company of Canada
510 Burrard Street, 3rd Floor
Vancouver, BC V6C 3B9
Attention: General Manager, Corporate Trust

As of February 1, 2021, a total of 2,694,575 Warrants remain outstanding. If all outstanding Warrants are exercised, proceeds to the Company will total $5,389,150; however there can be no assurance that any of the Warrants will be exercised prior to March 8, 2021.

About Perimeter Medical Imaging AI, Inc.

Perimeter Medical Imaging AI (TSX-V:PINK)(OTC:PYNKF)(FSE:4PC) is a Toronto-based company with U.S. headquarters in Dallas, Texas that is developing, with plans to commercialize, advanced imaging tools that allow surgeons, radiologists, and pathologists to visualize microscopic tissue structures during a clinical procedure. Perimeter’s OTIS™ platform is a point-of-care imaging system that provides clinicians with real-time, ultra-high-resolution, sub-surface image volumes of the margin (1-2 mm below the surface) of an excised tissue specimen. The ability to visualize microscopic tissue structures during a clinical procedure in addition to standard of care tissue assessment for decision making during the procedure has the potential to result in better long-term outcomes for patients and lower costs to the healthcare system. Perimeter’s OTIS™ platform is cleared by the FDA as an imaging tool in the evaluation of excised human tissue microstructure by providing two-dimensional, cross-sectional, real-time depth visualization, with image review manipulation software for identifying and annotating regions of interest. In addition, Perimeter is developing advanced artificial intelligence/machine learning image assessment tools intended to increase the efficiency of review.

Perimeter’s ticker symbol “PINK” is a reference to the pink ribbons used during Breast Cancer Awareness Month by the Canadian Cancer Society and the American Cancer Society, driving home the company’s dedication to helping surgeons, radiologists and pathologists use Perimeter’s imaging technology and AI (Artificial Intelligence) in the fight against breast cancer, which is estimated to account for 30% of all female cancer diagnoses this year.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains statements that may constitute “forward-looking information” within the meaning of applicable Canadian securities legislation. In this news release, words such as “may”, “would”, “could”, “will”, “likely”, “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate” and similar words and the negative form thereof are used to identify forward-looking statements. . Forward-looking information may relate to management’s future outlook and anticipated events or results, and may include statements or information regarding the total proceeds that the Company may raise upon exercise of the Warrants. These forward-looking statements are founded on the basis of expectations and assumptions made by the Company which include, but are not limited to, the decision of holders of Warrants to exercise their Warrants and the successful implementation of Perimeter’s commercialization strategy, generally. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described the joint information circular dated May 12, 2020, prepared in respect of the securityholder meetings held on June 17, 2020 a copy of which is available on Perimeter's SEDAR profile at www.sedar.com, and could cause actual events or results to differ materially from those projected in any forward-looking statements. In particular, we note the risk that our technology may not achieve the anticipated benefits in terms of surgical outcomes. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005963/en/

FAQ

What is the new expiry date for Perimeter Medical's warrants?

The new expiry date for the warrants is March 8, 2021, at 4:00 p.m. Toronto Time.

How much could Perimeter Medical raise from the warrant exercise?

Perimeter Medical could raise approximately $5.39 million if all outstanding warrants are exercised.

What is the exercise price for the warrants issued by Perimeter Medical?

The exercise price for the warrants is $2.00 per common share.

What triggered the acceleration of the warrants' expiry date for Perimeter Medical?

The acceleration was triggered because the 15-day volume-weighted average trading price of the common shares exceeded $3.00.

How many warrants are outstanding for Perimeter Medical?

As of February 1, 2021, there are 2,694,575 warrants remaining outstanding.